nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.019	0.0317	CbGbCtD
Bortezomib—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.019	0.0317	CbGbCtD
Bortezomib—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0187	0.0313	CbGbCtD
Bortezomib—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0176	0.0294	CbGbCtD
Bortezomib—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0173	0.0288	CbGbCtD
Bortezomib—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0162	0.0271	CbGbCtD
Bortezomib—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0162	0.0271	CbGbCtD
Bortezomib—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0159	0.0266	CbGbCtD
Bortezomib—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0159	0.0266	CbGbCtD
Bortezomib—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0156	0.026	CbGbCtD
Bortezomib—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0147	0.0245	CbGbCtD
Bortezomib—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0146	0.0244	CbGbCtD
Bortezomib—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0146	0.0244	CbGbCtD
Bortezomib—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0144	0.024	CbGbCtD
Bortezomib—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0144	0.024	CbGbCtD
Bortezomib—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0142	0.0238	CbGbCtD
Bortezomib—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.0138	0.023	CbGbCtD
Bortezomib—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0137	0.0229	CbGbCtD
Bortezomib—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0134	0.0223	CbGbCtD
Bortezomib—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0134	0.0223	CbGbCtD
Bortezomib—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0133	0.0223	CbGbCtD
Bortezomib—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0132	0.0221	CbGbCtD
Bortezomib—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0132	0.0221	CbGbCtD
Bortezomib—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0123	0.0206	CbGbCtD
Bortezomib—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0121	0.0202	CbGbCtD
Bortezomib—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0121	0.0202	CbGbCtD
Bortezomib—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0121	0.0201	CbGbCtD
Bortezomib—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0121	0.0201	CbGbCtD
Bortezomib—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0116	0.0193	CbGbCtD
Bortezomib—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0114	0.0191	CbGbCtD
Bortezomib—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0111	0.0186	CbGbCtD
Bortezomib—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0111	0.0185	CbGbCtD
Bortezomib—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0104	0.0174	CbGbCtD
Bortezomib—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0101	0.0169	CbGbCtD
Bortezomib—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.01	0.0167	CbGbCtD
Bortezomib—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.01	0.0167	CbGbCtD
Bortezomib—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00961	0.0161	CbGbCtD
Bortezomib—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00917	0.0153	CbGbCtD
Bortezomib—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00917	0.0153	CbGbCtD
Bortezomib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00905	0.0151	CbGbCtD
Bortezomib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00851	0.0142	CbGbCtD
Bortezomib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00851	0.0142	CbGbCtD
Bortezomib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00769	0.0129	CbGbCtD
Bortezomib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00769	0.0129	CbGbCtD
Bortezomib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00664	0.0111	CbGbCtD
Bortezomib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00645	0.0108	CbGbCtD
Bortezomib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00583	0.00974	CbGbCtD
Bortezomib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00583	0.00974	CbGbCtD
Bortezomib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00559	0.00934	CbGbCtD
Bortezomib—CTSG—blood plasma—acquired immunodeficiency syndrome	0.004	0.0423	CbGeAlD
Bortezomib—CTSG—skin of body—acquired immunodeficiency syndrome	0.00192	0.0203	CbGeAlD
Bortezomib—PSMA1—skin of body—acquired immunodeficiency syndrome	0.00185	0.0195	CbGeAlD
Bortezomib—PSMD1—retina—acquired immunodeficiency syndrome	0.00177	0.0187	CbGeAlD
Bortezomib—PSMD2—retina—acquired immunodeficiency syndrome	0.00156	0.0165	CbGeAlD
Bortezomib—CTSG—lymphoid tissue—acquired immunodeficiency syndrome	0.00156	0.0165	CbGeAlD
Bortezomib—PSMA1—lymphoid tissue—acquired immunodeficiency syndrome	0.0015	0.0158	CbGeAlD
Bortezomib—PSMA1—digestive system—acquired immunodeficiency syndrome	0.00148	0.0156	CbGeAlD
Bortezomib—CTSG—blood—acquired immunodeficiency syndrome	0.00147	0.0155	CbGeAlD
Bortezomib—CTSG—bone marrow—acquired immunodeficiency syndrome	0.00142	0.015	CbGeAlD
Bortezomib—PSMD2—skin of body—acquired immunodeficiency syndrome	0.00137	0.0145	CbGeAlD
Bortezomib—PSMA1—bone marrow—acquired immunodeficiency syndrome	0.00136	0.0144	CbGeAlD
Bortezomib—CTSG—vagina—acquired immunodeficiency syndrome	0.00136	0.0144	CbGeAlD
Bortezomib—CTSG—lung—acquired immunodeficiency syndrome	0.00128	0.0136	CbGeAlD
Bortezomib—PSMA1—lung—acquired immunodeficiency syndrome	0.00123	0.013	CbGeAlD
Bortezomib—PSMD1—blood—acquired immunodeficiency syndrome	0.00118	0.0125	CbGeAlD
Bortezomib—PSMB2—retina—acquired immunodeficiency syndrome	0.00117	0.0124	CbGeAlD
Bortezomib—PSMD1—bone marrow—acquired immunodeficiency syndrome	0.00114	0.0121	CbGeAlD
Bortezomib—PSMA1—nervous system—acquired immunodeficiency syndrome	0.00114	0.0121	CbGeAlD
Bortezomib—PSMD1—spinal cord—acquired immunodeficiency syndrome	0.00114	0.012	CbGeAlD
Bortezomib—PSMD2—lymphoid tissue—acquired immunodeficiency syndrome	0.00111	0.0118	CbGeAlD
Bortezomib—PSMA1—central nervous system—acquired immunodeficiency syndrome	0.0011	0.0116	CbGeAlD
Bortezomib—PSMD2—digestive system—acquired immunodeficiency syndrome	0.0011	0.0116	CbGeAlD
Bortezomib—PSMD1—vagina—acquired immunodeficiency syndrome	0.00109	0.0116	CbGeAlD
Bortezomib—PSMB1—skin of body—acquired immunodeficiency syndrome	0.00105	0.0111	CbGeAlD
Bortezomib—PSMD2—blood—acquired immunodeficiency syndrome	0.00105	0.0111	CbGeAlD
Bortezomib—PSMB8—blood—acquired immunodeficiency syndrome	0.00104	0.011	CbGeAlD
Bortezomib—PSMD1—lung—acquired immunodeficiency syndrome	0.00104	0.011	CbGeAlD
Bortezomib—PSMB2—skin of body—acquired immunodeficiency syndrome	0.00103	0.0109	CbGeAlD
Bortezomib—PSMD2—bone marrow—acquired immunodeficiency syndrome	0.00101	0.0107	CbGeAlD
Bortezomib—PSMD2—spinal cord—acquired immunodeficiency syndrome	0.00101	0.0107	CbGeAlD
Bortezomib—PSMB8—bone marrow—acquired immunodeficiency syndrome	0.00101	0.0106	CbGeAlD
Bortezomib—PSMD2—vagina—acquired immunodeficiency syndrome	0.00097	0.0103	CbGeAlD
Bortezomib—PSMB8—vagina—acquired immunodeficiency syndrome	0.000964	0.0102	CbGeAlD
Bortezomib—PSMB5—blood—acquired immunodeficiency syndrome	0.000919	0.00971	CbGeAlD
Bortezomib—PSMD2—lung—acquired immunodeficiency syndrome	0.000917	0.0097	CbGeAlD
Bortezomib—PSMB8—lung—acquired immunodeficiency syndrome	0.000912	0.00964	CbGeAlD
Bortezomib—PSMB5—bone marrow—acquired immunodeficiency syndrome	0.000889	0.0094	CbGeAlD
Bortezomib—PSMB5—spinal cord—acquired immunodeficiency syndrome	0.000885	0.00936	CbGeAlD
Bortezomib—CTSG—lymph node—acquired immunodeficiency syndrome	0.000879	0.00929	CbGeAlD
Bortezomib—PSMA1—brain—acquired immunodeficiency syndrome	0.000873	0.00923	CbGeAlD
Bortezomib—PSMB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000853	0.00902	CbGeAlD
Bortezomib—PSMB5—vagina—acquired immunodeficiency syndrome	0.000851	0.009	CbGeAlD
Bortezomib—PSMD2—nervous system—acquired immunodeficiency syndrome	0.000849	0.00898	CbGeAlD
Bortezomib—PSMA1—lymph node—acquired immunodeficiency syndrome	0.000844	0.00892	CbGeAlD
Bortezomib—PSMB1—digestive system—acquired immunodeficiency syndrome	0.000843	0.00891	CbGeAlD
Bortezomib—PSMB2—lymphoid tissue—acquired immunodeficiency syndrome	0.000832	0.0088	CbGeAlD
Bortezomib—PSMB2—digestive system—acquired immunodeficiency syndrome	0.000822	0.0087	CbGeAlD
Bortezomib—PSMD2—central nervous system—acquired immunodeficiency syndrome	0.000818	0.00865	CbGeAlD
Bortezomib—PSMB5—lung—acquired immunodeficiency syndrome	0.000805	0.00852	CbGeAlD
Bortezomib—PSMB1—blood—acquired immunodeficiency syndrome	0.000803	0.00849	CbGeAlD
Bortezomib—PSMB2—blood—acquired immunodeficiency syndrome	0.000783	0.00828	CbGeAlD
Bortezomib—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.000781	0.00826	CbGeAlD
Bortezomib—PSMB1—bone marrow—acquired immunodeficiency syndrome	0.000777	0.00822	CbGeAlD
Bortezomib—PSMB1—spinal cord—acquired immunodeficiency syndrome	0.000774	0.00818	CbGeAlD
Bortezomib—PSMB2—bone marrow—acquired immunodeficiency syndrome	0.000758	0.00802	CbGeAlD
Bortezomib—PSMB2—spinal cord—acquired immunodeficiency syndrome	0.000755	0.00798	CbGeAlD
Bortezomib—PSMB1—vagina—acquired immunodeficiency syndrome	0.000744	0.00787	CbGeAlD
Bortezomib—PSMD1—brain—acquired immunodeficiency syndrome	0.000733	0.00775	CbGeAlD
Bortezomib—PSMB2—vagina—acquired immunodeficiency syndrome	0.000726	0.00768	CbGeAlD
Bortezomib—SLC31A1—digestive system—acquired immunodeficiency syndrome	0.000712	0.00753	CbGeAlD
Bortezomib—PSMD1—lymph node—acquired immunodeficiency syndrome	0.000708	0.00749	CbGeAlD
Bortezomib—PSMB1—lung—acquired immunodeficiency syndrome	0.000704	0.00744	CbGeAlD
Bortezomib—PSMB2—lung—acquired immunodeficiency syndrome	0.000687	0.00726	CbGeAlD
Bortezomib—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.000681	0.00721	CbGeAlD
Bortezomib—SLC31A1—blood—acquired immunodeficiency syndrome	0.000678	0.00717	CbGeAlD
Bortezomib—SLC31A1—bone marrow—acquired immunodeficiency syndrome	0.000656	0.00694	CbGeAlD
Bortezomib—SLC31A1—spinal cord—acquired immunodeficiency syndrome	0.000654	0.00691	CbGeAlD
Bortezomib—PSMB1—nervous system—acquired immunodeficiency syndrome	0.000652	0.00689	CbGeAlD
Bortezomib—PSMD2—brain—acquired immunodeficiency syndrome	0.000649	0.00687	CbGeAlD
Bortezomib—PSMB8—brain—acquired immunodeficiency syndrome	0.000645	0.00682	CbGeAlD
Bortezomib—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000638	0.00674	CbGeAlD
Bortezomib—PSMB2—nervous system—acquired immunodeficiency syndrome	0.000636	0.00673	CbGeAlD
Bortezomib—SLC31A1—vagina—acquired immunodeficiency syndrome	0.000629	0.00665	CbGeAlD
Bortezomib—PSMB1—central nervous system—acquired immunodeficiency syndrome	0.000628	0.00664	CbGeAlD
Bortezomib—PSMD2—lymph node—acquired immunodeficiency syndrome	0.000627	0.00663	CbGeAlD
Bortezomib—PSMB8—lymph node—acquired immunodeficiency syndrome	0.000623	0.00659	CbGeAlD
Bortezomib—PTGS1—endothelium—acquired immunodeficiency syndrome	0.000622	0.00658	CbGeAlD
Bortezomib—PSMB2—central nervous system—acquired immunodeficiency syndrome	0.000612	0.00648	CbGeAlD
Bortezomib—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000605	0.0064	CbGeAlD
Bortezomib—SLC31A1—lung—acquired immunodeficiency syndrome	0.000595	0.00629	CbGeAlD
Bortezomib—PSMB5—brain—acquired immunodeficiency syndrome	0.00057	0.00603	CbGeAlD
Bortezomib—PTGS1—blood plasma—acquired immunodeficiency syndrome	0.000553	0.00584	CbGeAlD
Bortezomib—PSMB5—lymph node—acquired immunodeficiency syndrome	0.000551	0.00582	CbGeAlD
Bortezomib—SLC31A1—nervous system—acquired immunodeficiency syndrome	0.000551	0.00582	CbGeAlD
Bortezomib—SLC31A1—central nervous system—acquired immunodeficiency syndrome	0.00053	0.00561	CbGeAlD
Bortezomib—PSMB1—brain—acquired immunodeficiency syndrome	0.000498	0.00527	CbGeAlD
Bortezomib—PSMB2—brain—acquired immunodeficiency syndrome	0.000486	0.00514	CbGeAlD
Bortezomib—PSMB1—lymph node—acquired immunodeficiency syndrome	0.000481	0.00509	CbGeAlD
Bortezomib—PSMB2—lymph node—acquired immunodeficiency syndrome	0.00047	0.00497	CbGeAlD
Bortezomib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000462	0.00488	CbGeAlD
Bortezomib—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000454	0.0048	CbGeAlD
Bortezomib—SLC31A1—brain—acquired immunodeficiency syndrome	0.000421	0.00445	CbGeAlD
Bortezomib—SLC31A1—lymph node—acquired immunodeficiency syndrome	0.000407	0.0043	CbGeAlD
Bortezomib—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000302	0.0032	CbGeAlD
Bortezomib—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.0003	0.00317	CbGeAlD
Bortezomib—CYP2C19—blood—acquired immunodeficiency syndrome	0.000286	0.00302	CbGeAlD
Bortezomib—PTGS1—skin of body—acquired immunodeficiency syndrome	0.000266	0.00281	CbGeAlD
Bortezomib—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000265	0.0028	CbGeAlD
Bortezomib—CYP2C8—blood—acquired immunodeficiency syndrome	0.00025	0.00264	CbGeAlD
Bortezomib—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000245	0.00259	CbGeAlD
Bortezomib—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.000242	0.00256	CbGeAlD
Bortezomib—CYP1A2—blood—acquired immunodeficiency syndrome	0.000234	0.00247	CbGeAlD
Bortezomib—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000233	0.00246	CbGeAlD
Bortezomib—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000231	0.00245	CbGeAlD
Bortezomib—CYP1A1—blood—acquired immunodeficiency syndrome	0.00023	0.00244	CbGeAlD
Bortezomib—CYP2C9—blood—acquired immunodeficiency syndrome	0.000222	0.00234	CbGeAlD
Bortezomib—CYP1A1—vagina—acquired immunodeficiency syndrome	0.000214	0.00226	CbGeAlD
Bortezomib—PTGS1—digestive system—acquired immunodeficiency syndrome	0.000212	0.00225	CbGeAlD
Bortezomib—CYP1A2—lung—acquired immunodeficiency syndrome	0.000205	0.00217	CbGeAlD
Bortezomib—PTGS1—blood—acquired immunodeficiency syndrome	0.000202	0.00214	CbGeAlD
Bortezomib—CYP1A1—lung—acquired immunodeficiency syndrome	0.000202	0.00214	CbGeAlD
Bortezomib—PTGS1—spinal cord—acquired immunodeficiency syndrome	0.000195	0.00206	CbGeAlD
Bortezomib—PTGS1—vagina—acquired immunodeficiency syndrome	0.000188	0.00198	CbGeAlD
Bortezomib—CYP1A1—nervous system—acquired immunodeficiency syndrome	0.000187	0.00198	CbGeAlD
Bortezomib—CYP1A1—central nervous system—acquired immunodeficiency syndrome	0.00018	0.0019	CbGeAlD
Bortezomib—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000177	0.00188	CbGeAlD
Bortezomib—PTGS1—lung—acquired immunodeficiency syndrome	0.000177	0.00188	CbGeAlD
Bortezomib—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000175	0.00185	CbGeAlD
Bortezomib—CYP3A4—blood—acquired immunodeficiency syndrome	0.000169	0.00179	CbGeAlD
Bortezomib—CYP2D6—blood—acquired immunodeficiency syndrome	0.000166	0.00176	CbGeAlD
Bortezomib—PTGS1—nervous system—acquired immunodeficiency syndrome	0.000164	0.00174	CbGeAlD
Bortezomib—PTGS1—central nervous system—acquired immunodeficiency syndrome	0.000158	0.00167	CbGeAlD
Bortezomib—CYP2C8—brain—acquired immunodeficiency syndrome	0.000155	0.00164	CbGeAlD
Bortezomib—CYP1A1—brain—acquired immunodeficiency syndrome	0.000143	0.00151	CbGeAlD
Bortezomib—CYP1A1—lymph node—acquired immunodeficiency syndrome	0.000138	0.00146	CbGeAlD
Bortezomib—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000137	0.00145	CbGeAlD
Bortezomib—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000135	0.00143	CbGeAlD
Bortezomib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000132	0.0014	CbGeAlD
Bortezomib—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.00013	0.00138	CbGeAlD
Bortezomib—PTGS1—brain—acquired immunodeficiency syndrome	0.000126	0.00133	CbGeAlD
Bortezomib—PTGS1—lymph node—acquired immunodeficiency syndrome	0.000121	0.00128	CbGeAlD
Bortezomib—CYP2D6—brain—acquired immunodeficiency syndrome	0.000103	0.00109	CbGeAlD
Bortezomib—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	6.15e-05	0.000271	CcSEcCtD
Bortezomib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	6.14e-05	0.000271	CcSEcCtD
Bortezomib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	6.14e-05	0.000271	CcSEcCtD
Bortezomib—Chest pain—Ritonavir—acquired immunodeficiency syndrome	6.14e-05	0.000271	CcSEcCtD
Bortezomib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	6.13e-05	0.00027	CcSEcCtD
Bortezomib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	6.13e-05	0.00027	CcSEcCtD
Bortezomib—Anxiety—Ritonavir—acquired immunodeficiency syndrome	6.12e-05	0.00027	CcSEcCtD
Bortezomib—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	6.11e-05	0.000269	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	6.1e-05	0.000269	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	6.08e-05	0.000268	CcSEcCtD
Bortezomib—Pruritus—Abacavir—acquired immunodeficiency syndrome	6.08e-05	0.000268	CcSEcCtD
Bortezomib—Fatigue—Indinavir—acquired immunodeficiency syndrome	6.07e-05	0.000268	CcSEcCtD
Bortezomib—Anorexia—Delavirdine—acquired immunodeficiency syndrome	6.07e-05	0.000267	CcSEcCtD
Bortezomib—Discomfort—Ritonavir—acquired immunodeficiency syndrome	6.07e-05	0.000267	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	6.07e-05	0.000267	CcSEcCtD
Bortezomib—Cough—Saquinavir—acquired immunodeficiency syndrome	6.06e-05	0.000267	CcSEcCtD
Bortezomib—Angioedema—Lamivudine—acquired immunodeficiency syndrome	6.06e-05	0.000267	CcSEcCtD
Bortezomib—Constipation—Indinavir—acquired immunodeficiency syndrome	6.03e-05	0.000265	CcSEcCtD
Bortezomib—Pain—Indinavir—acquired immunodeficiency syndrome	6.03e-05	0.000265	CcSEcCtD
Bortezomib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	6.02e-05	0.000265	CcSEcCtD
Bortezomib—Urticaria—Zidovudine—acquired immunodeficiency syndrome	6.02e-05	0.000265	CcSEcCtD
Bortezomib—Convulsion—Saquinavir—acquired immunodeficiency syndrome	6.02e-05	0.000265	CcSEcCtD
Bortezomib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	6e-05	0.000264	CcSEcCtD
Bortezomib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	5.99e-05	0.000264	CcSEcCtD
Bortezomib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	5.99e-05	0.000264	CcSEcCtD
Bortezomib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	5.98e-05	0.000264	CcSEcCtD
Bortezomib—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	5.98e-05	0.000263	CcSEcCtD
Bortezomib—Malaise—Lamivudine—acquired immunodeficiency syndrome	5.98e-05	0.000263	CcSEcCtD
Bortezomib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	5.96e-05	0.000263	CcSEcCtD
Bortezomib—Nausea—Didanosine—acquired immunodeficiency syndrome	5.96e-05	0.000263	CcSEcCtD
Bortezomib—Vertigo—Lamivudine—acquired immunodeficiency syndrome	5.95e-05	0.000262	CcSEcCtD
Bortezomib—Hypotension—Delavirdine—acquired immunodeficiency syndrome	5.95e-05	0.000262	CcSEcCtD
Bortezomib—Syncope—Lamivudine—acquired immunodeficiency syndrome	5.94e-05	0.000262	CcSEcCtD
Bortezomib—Confusional state—Ritonavir—acquired immunodeficiency syndrome	5.94e-05	0.000262	CcSEcCtD
Bortezomib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	5.94e-05	0.000261	CcSEcCtD
Bortezomib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	5.93e-05	0.000261	CcSEcCtD
Bortezomib—Chest pain—Saquinavir—acquired immunodeficiency syndrome	5.91e-05	0.00026	CcSEcCtD
Bortezomib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	5.91e-05	0.00026	CcSEcCtD
Bortezomib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	5.91e-05	0.00026	CcSEcCtD
Bortezomib—Anxiety—Saquinavir—acquired immunodeficiency syndrome	5.89e-05	0.00026	CcSEcCtD
Bortezomib—Oedema—Ritonavir—acquired immunodeficiency syndrome	5.89e-05	0.000259	CcSEcCtD
Bortezomib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	5.88e-05	0.000259	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	5.87e-05	0.000259	CcSEcCtD
Bortezomib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	5.86e-05	0.000258	CcSEcCtD
Bortezomib—Discomfort—Saquinavir—acquired immunodeficiency syndrome	5.84e-05	0.000257	CcSEcCtD
Bortezomib—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	5.82e-05	0.000257	CcSEcCtD
Bortezomib—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	5.81e-05	0.000256	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	5.8e-05	0.000256	CcSEcCtD
Bortezomib—Shock—Ritonavir—acquired immunodeficiency syndrome	5.8e-05	0.000255	CcSEcCtD
Bortezomib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	5.79e-05	0.000255	CcSEcCtD
Bortezomib—Cough—Lamivudine—acquired immunodeficiency syndrome	5.78e-05	0.000255	CcSEcCtD
Bortezomib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	5.78e-05	0.000255	CcSEcCtD
Bortezomib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	5.78e-05	0.000254	CcSEcCtD
Bortezomib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	5.77e-05	0.000254	CcSEcCtD
Bortezomib—Dizziness—Stavudine—acquired immunodeficiency syndrome	5.76e-05	0.000254	CcSEcCtD
Bortezomib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	5.76e-05	0.000254	CcSEcCtD
Bortezomib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	5.76e-05	0.000254	CcSEcCtD
Bortezomib—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	5.75e-05	0.000253	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	5.75e-05	0.000253	CcSEcCtD
Bortezomib—Convulsion—Lamivudine—acquired immunodeficiency syndrome	5.74e-05	0.000253	CcSEcCtD
Bortezomib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	5.74e-05	0.000253	CcSEcCtD
Bortezomib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	5.74e-05	0.000253	CcSEcCtD
Bortezomib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	5.72e-05	0.000252	CcSEcCtD
Bortezomib—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	5.72e-05	0.000252	CcSEcCtD
Bortezomib—Confusional state—Saquinavir—acquired immunodeficiency syndrome	5.72e-05	0.000252	CcSEcCtD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	5.7e-05	0.000715	CbGpPWpGaD
Bortezomib—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	5.69e-05	0.000251	CcSEcCtD
Bortezomib—Pain—Efavirenz—acquired immunodeficiency syndrome	5.69e-05	0.000251	CcSEcCtD
Bortezomib—Constipation—Efavirenz—acquired immunodeficiency syndrome	5.69e-05	0.000251	CcSEcCtD
Bortezomib—Rash—Nevirapine—acquired immunodeficiency syndrome	5.69e-05	0.000251	CcSEcCtD
Bortezomib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	5.69e-05	0.00025	CcSEcCtD
Bortezomib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	5.68e-05	0.00025	CcSEcCtD
Bortezomib—Dizziness—Abacavir—acquired immunodeficiency syndrome	5.68e-05	0.00025	CcSEcCtD
Bortezomib—Oedema—Saquinavir—acquired immunodeficiency syndrome	5.67e-05	0.00025	CcSEcCtD
Bortezomib—Headache—Nevirapine—acquired immunodeficiency syndrome	5.66e-05	0.000249	CcSEcCtD
Bortezomib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	5.64e-05	0.000249	CcSEcCtD
Bortezomib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	5.64e-05	0.000249	CcSEcCtD
Bortezomib—Chest pain—Lamivudine—acquired immunodeficiency syndrome	5.64e-05	0.000249	CcSEcCtD
Bortezomib—Infection—Saquinavir—acquired immunodeficiency syndrome	5.63e-05	0.000248	CcSEcCtD
Bortezomib—Anxiety—Lamivudine—acquired immunodeficiency syndrome	5.62e-05	0.000248	CcSEcCtD
Bortezomib—Anorexia—Ritonavir—acquired immunodeficiency syndrome	5.61e-05	0.000247	CcSEcCtD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	5.61e-05	0.000705	CbGpPWpGaD
Bortezomib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	5.61e-05	0.000247	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	5.6e-05	0.000247	CcSEcCtD
Bortezomib—PSMB2—Immune System—MBL2—acquired immunodeficiency syndrome	5.6e-05	0.000703	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—MBL2—acquired immunodeficiency syndrome	5.6e-05	0.000703	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—MBL2—acquired immunodeficiency syndrome	5.6e-05	0.000703	CbGpPWpGaD
Bortezomib—Urticaria—Indinavir—acquired immunodeficiency syndrome	5.6e-05	0.000247	CcSEcCtD
Bortezomib—Shock—Saquinavir—acquired immunodeficiency syndrome	5.58e-05	0.000246	CcSEcCtD
Bortezomib—Discomfort—Lamivudine—acquired immunodeficiency syndrome	5.57e-05	0.000246	CcSEcCtD
Bortezomib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	5.57e-05	0.000245	CcSEcCtD
Bortezomib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	5.57e-05	0.000245	CcSEcCtD
Bortezomib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	5.56e-05	0.000245	CcSEcCtD
Bortezomib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	5.56e-05	0.000245	CcSEcCtD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—IFNG—acquired immunodeficiency syndrome	5.56e-05	0.000698	CbGpPWpGaD
Bortezomib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	5.55e-05	0.000244	CcSEcCtD
Bortezomib—Vomiting—Stavudine—acquired immunodeficiency syndrome	5.54e-05	0.000244	CcSEcCtD
Bortezomib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	5.54e-05	0.000244	CcSEcCtD
Bortezomib—PSMB8—Immune System—MBL2—acquired immunodeficiency syndrome	5.52e-05	0.000693	CbGpPWpGaD
Bortezomib—Rash—Nelfinavir—acquired immunodeficiency syndrome	5.51e-05	0.000243	CcSEcCtD
Bortezomib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	5.51e-05	0.000243	CcSEcCtD
Bortezomib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	5.51e-05	0.000243	CcSEcCtD
Bortezomib—Hypotension—Ritonavir—acquired immunodeficiency syndrome	5.5e-05	0.000242	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	5.5e-05	0.000242	CcSEcCtD
Bortezomib—Rash—Stavudine—acquired immunodeficiency syndrome	5.5e-05	0.000242	CcSEcCtD
Bortezomib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	5.49e-05	0.000242	CcSEcCtD
Bortezomib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	5.49e-05	0.000242	CcSEcCtD
Bortezomib—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	5.49e-05	0.000242	CcSEcCtD
Bortezomib—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	5.48e-05	0.000241	CcSEcCtD
Bortezomib—Headache—Nelfinavir—acquired immunodeficiency syndrome	5.48e-05	0.000241	CcSEcCtD
Bortezomib—Headache—Stavudine—acquired immunodeficiency syndrome	5.46e-05	0.000241	CcSEcCtD
Bortezomib—Vomiting—Abacavir—acquired immunodeficiency syndrome	5.46e-05	0.00024	CcSEcCtD
Bortezomib—Confusional state—Lamivudine—acquired immunodeficiency syndrome	5.45e-05	0.00024	CcSEcCtD
Bortezomib—Pain—Delavirdine—acquired immunodeficiency syndrome	5.45e-05	0.00024	CcSEcCtD
Bortezomib—Constipation—Delavirdine—acquired immunodeficiency syndrome	5.45e-05	0.00024	CcSEcCtD
Bortezomib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	5.44e-05	0.00024	CcSEcCtD
Bortezomib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	5.44e-05	0.000239	CcSEcCtD
Bortezomib—Rash—Abacavir—acquired immunodeficiency syndrome	5.41e-05	0.000238	CcSEcCtD
Bortezomib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	5.41e-05	0.000238	CcSEcCtD
Bortezomib—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	5.41e-05	0.000238	CcSEcCtD
Bortezomib—Oedema—Lamivudine—acquired immunodeficiency syndrome	5.41e-05	0.000238	CcSEcCtD
Bortezomib—Anorexia—Saquinavir—acquired immunodeficiency syndrome	5.4e-05	0.000238	CcSEcCtD
Bortezomib—Headache—Abacavir—acquired immunodeficiency syndrome	5.38e-05	0.000237	CcSEcCtD
Bortezomib—Infection—Lamivudine—acquired immunodeficiency syndrome	5.37e-05	0.000237	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	5.37e-05	0.000236	CcSEcCtD
Bortezomib—Nausea—Nevirapine—acquired immunodeficiency syndrome	5.36e-05	0.000236	CcSEcCtD
Bortezomib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	5.36e-05	0.000236	CcSEcCtD
Bortezomib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	5.33e-05	0.000235	CcSEcCtD
Bortezomib—Shock—Lamivudine—acquired immunodeficiency syndrome	5.32e-05	0.000234	CcSEcCtD
Bortezomib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	5.3e-05	0.000234	CcSEcCtD
Bortezomib—Hypotension—Saquinavir—acquired immunodeficiency syndrome	5.3e-05	0.000233	CcSEcCtD
Bortezomib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	5.3e-05	0.000233	CcSEcCtD
Bortezomib—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	5.29e-05	0.000233	CcSEcCtD
Bortezomib—Urticaria—Efavirenz—acquired immunodeficiency syndrome	5.29e-05	0.000233	CcSEcCtD
Bortezomib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	5.26e-05	0.000232	CcSEcCtD
Bortezomib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	5.26e-05	0.000232	CcSEcCtD
Bortezomib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	5.25e-05	0.000231	CcSEcCtD
Bortezomib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	5.25e-05	0.000231	CcSEcCtD
Bortezomib—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	5.25e-05	0.000231	CcSEcCtD
Bortezomib—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	5.23e-05	0.00023	CcSEcCtD
Bortezomib—PSMA1—Immune System—IFNA1—acquired immunodeficiency syndrome	5.22e-05	0.000655	CbGpPWpGaD
Bortezomib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	5.21e-05	0.000229	CcSEcCtD
Bortezomib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	5.19e-05	0.000229	CcSEcCtD
Bortezomib—PSMD1—Immune System—IFNA1—acquired immunodeficiency syndrome	5.19e-05	0.000652	CbGpPWpGaD
Bortezomib—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	5.19e-05	0.000229	CcSEcCtD
Bortezomib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	5.19e-05	0.000228	CcSEcCtD
Bortezomib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	5.18e-05	0.000228	CcSEcCtD
Bortezomib—Nausea—Stavudine—acquired immunodeficiency syndrome	5.18e-05	0.000228	CcSEcCtD
Bortezomib—PSMD2—Immune System—IFNA1—acquired immunodeficiency syndrome	5.17e-05	0.000649	CbGpPWpGaD
Bortezomib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	5.17e-05	0.000228	CcSEcCtD
Bortezomib—PSMB2—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	5.16e-05	0.000648	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	5.16e-05	0.000648	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	5.16e-05	0.000648	CbGpPWpGaD
Bortezomib—Anorexia—Lamivudine—acquired immunodeficiency syndrome	5.16e-05	0.000227	CcSEcCtD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.15e-05	0.000646	CbGpPWpGaD
Bortezomib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	5.13e-05	0.000226	CcSEcCtD
Bortezomib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	5.12e-05	0.000226	CcSEcCtD
Bortezomib—PSMB1—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	5.1e-05	0.000641	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	5.1e-05	0.000641	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	5.1e-05	0.000641	CbGpPWpGaD
Bortezomib—Nausea—Abacavir—acquired immunodeficiency syndrome	5.1e-05	0.000225	CcSEcCtD
Bortezomib—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	5.09e-05	0.000224	CcSEcCtD
Bortezomib—PSMB8—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	5.09e-05	0.000639	CbGpPWpGaD
Bortezomib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	5.09e-05	0.000224	CcSEcCtD
Bortezomib—PSMB1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.08e-05	0.000638	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.08e-05	0.000638	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.08e-05	0.000638	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.08e-05	0.000638	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.08e-05	0.000638	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.08e-05	0.000638	CbGpPWpGaD
Bortezomib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	5.08e-05	0.000224	CcSEcCtD
Bortezomib—PSMA1—Immune System—CD79A—acquired immunodeficiency syndrome	5.07e-05	0.000636	CbGpPWpGaD
Bortezomib—Urticaria—Delavirdine—acquired immunodeficiency syndrome	5.06e-05	0.000223	CcSEcCtD
Bortezomib—Asthenia—Indinavir—acquired immunodeficiency syndrome	5.06e-05	0.000223	CcSEcCtD
Bortezomib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	5.05e-05	0.000223	CcSEcCtD
Bortezomib—Hypotension—Lamivudine—acquired immunodeficiency syndrome	5.05e-05	0.000223	CcSEcCtD
Bortezomib—PSMD1—Immune System—CD79A—acquired immunodeficiency syndrome	5.04e-05	0.000633	CbGpPWpGaD
Bortezomib—Pain—Ritonavir—acquired immunodeficiency syndrome	5.04e-05	0.000222	CcSEcCtD
Bortezomib—Constipation—Ritonavir—acquired immunodeficiency syndrome	5.04e-05	0.000222	CcSEcCtD
Bortezomib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	5.04e-05	0.000222	CcSEcCtD
Bortezomib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	5.04e-05	0.000222	CcSEcCtD
Bortezomib—PSMA1—Disease—CXCR4—acquired immunodeficiency syndrome	5.03e-05	0.000632	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	5.03e-05	0.000632	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CD79A—acquired immunodeficiency syndrome	5.02e-05	0.00063	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.01e-05	0.000629	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.01e-05	0.000629	CbGpPWpGaD
Bortezomib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	5.01e-05	0.000221	CcSEcCtD
Bortezomib—PSMD1—Disease—CXCR4—acquired immunodeficiency syndrome	5.01e-05	0.000629	CbGpPWpGaD
Bortezomib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	4.99e-05	0.00022	CcSEcCtD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	4.99e-05	0.000626	CbGpPWpGaD
Bortezomib—Pruritus—Indinavir—acquired immunodeficiency syndrome	4.99e-05	0.00022	CcSEcCtD
Bortezomib—PSMD2—Disease—CXCR4—acquired immunodeficiency syndrome	4.98e-05	0.000626	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	4.94e-05	0.00062	CbGpPWpGaD
Bortezomib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	4.93e-05	0.000217	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	4.93e-05	0.000217	CcSEcCtD
Bortezomib—PSMB2—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	4.91e-05	0.000616	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	4.91e-05	0.000616	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	4.91e-05	0.000616	CbGpPWpGaD
Bortezomib—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	4.9e-05	0.000216	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	4.89e-05	0.000216	CcSEcCtD
Bortezomib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	4.89e-05	0.000215	CcSEcCtD
Bortezomib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	4.89e-05	0.000215	CcSEcCtD
Bortezomib—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	4.86e-05	0.000214	CcSEcCtD
Bortezomib—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	4.85e-05	0.000214	CcSEcCtD
Bortezomib—Pain—Saquinavir—acquired immunodeficiency syndrome	4.85e-05	0.000214	CcSEcCtD
Bortezomib—Constipation—Saquinavir—acquired immunodeficiency syndrome	4.85e-05	0.000214	CcSEcCtD
Bortezomib—PSMB8—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	4.84e-05	0.000608	CbGpPWpGaD
Bortezomib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	4.82e-05	0.000212	CcSEcCtD
Bortezomib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	4.82e-05	0.000212	CcSEcCtD
Bortezomib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	4.82e-05	0.000212	CcSEcCtD
Bortezomib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	4.82e-05	0.000212	CcSEcCtD
Bortezomib—PTGS1—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	4.81e-05	0.000604	CbGpPWpGaD
Bortezomib—Rash—Zidovudine—acquired immunodeficiency syndrome	4.78e-05	0.00021	CcSEcCtD
Bortezomib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	4.78e-05	0.00021	CcSEcCtD
Bortezomib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	4.77e-05	0.00021	CcSEcCtD
Bortezomib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	4.76e-05	0.00021	CcSEcCtD
Bortezomib—Headache—Zidovudine—acquired immunodeficiency syndrome	4.75e-05	0.000209	CcSEcCtD
Bortezomib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	4.71e-05	0.000207	CcSEcCtD
Bortezomib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	4.7e-05	0.000207	CcSEcCtD
Bortezomib—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	4.69e-05	0.000207	CcSEcCtD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	4.69e-05	0.000589	CbGpPWpGaD
Bortezomib—Urticaria—Ritonavir—acquired immunodeficiency syndrome	4.68e-05	0.000206	CcSEcCtD
Bortezomib—PTGS1—Metabolism—TAT—acquired immunodeficiency syndrome	4.68e-05	0.000587	CbGpPWpGaD
Bortezomib—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	4.67e-05	0.000206	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	4.67e-05	0.000206	CcSEcCtD
Bortezomib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	4.66e-05	0.000205	CcSEcCtD
Bortezomib—Dizziness—Indinavir—acquired immunodeficiency syndrome	4.66e-05	0.000205	CcSEcCtD
Bortezomib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	4.66e-05	0.000205	CcSEcCtD
Bortezomib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	4.66e-05	0.000205	CcSEcCtD
Bortezomib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	4.64e-05	0.000204	CcSEcCtD
Bortezomib—Pain—Lamivudine—acquired immunodeficiency syndrome	4.63e-05	0.000204	CcSEcCtD
Bortezomib—Constipation—Lamivudine—acquired immunodeficiency syndrome	4.63e-05	0.000204	CcSEcCtD
Bortezomib—PSMB5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.6e-05	0.000577	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.6e-05	0.000577	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.6e-05	0.000577	CbGpPWpGaD
Bortezomib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	4.57e-05	0.000201	CcSEcCtD
Bortezomib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	4.56e-05	0.000201	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.53e-05	0.000569	CbGpPWpGaD
Bortezomib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	4.51e-05	0.000198	CcSEcCtD
Bortezomib—Urticaria—Saquinavir—acquired immunodeficiency syndrome	4.5e-05	0.000198	CcSEcCtD
Bortezomib—Nausea—Zidovudine—acquired immunodeficiency syndrome	4.5e-05	0.000198	CcSEcCtD
Bortezomib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	4.48e-05	0.000197	CcSEcCtD
Bortezomib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	4.48e-05	0.000197	CcSEcCtD
Bortezomib—Vomiting—Indinavir—acquired immunodeficiency syndrome	4.48e-05	0.000197	CcSEcCtD
Bortezomib—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	4.46e-05	0.000196	CcSEcCtD
Bortezomib—Rash—Indinavir—acquired immunodeficiency syndrome	4.44e-05	0.000196	CcSEcCtD
Bortezomib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	4.44e-05	0.000196	CcSEcCtD
Bortezomib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	4.42e-05	0.000195	CcSEcCtD
Bortezomib—Headache—Indinavir—acquired immunodeficiency syndrome	4.41e-05	0.000194	CcSEcCtD
Bortezomib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	4.4e-05	0.000194	CcSEcCtD
Bortezomib—PSMB5—Immune System—CCR2—acquired immunodeficiency syndrome	4.39e-05	0.000552	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CCR2—acquired immunodeficiency syndrome	4.39e-05	0.000552	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CCR2—acquired immunodeficiency syndrome	4.39e-05	0.000552	CbGpPWpGaD
Bortezomib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	4.36e-05	0.000192	CcSEcCtD
Bortezomib—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	4.34e-05	0.000191	CcSEcCtD
Bortezomib—PSMB8—Immune System—CCR2—acquired immunodeficiency syndrome	4.33e-05	0.000544	CbGpPWpGaD
Bortezomib—Urticaria—Lamivudine—acquired immunodeficiency syndrome	4.3e-05	0.000189	CcSEcCtD
Bortezomib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	4.28e-05	0.000188	CcSEcCtD
Bortezomib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	4.28e-05	0.000188	CcSEcCtD
Bortezomib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	4.23e-05	0.000186	CcSEcCtD
Bortezomib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	4.23e-05	0.000186	CcSEcCtD
Bortezomib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	4.21e-05	0.000186	CcSEcCtD
Bortezomib—Rash—Efavirenz—acquired immunodeficiency syndrome	4.2e-05	0.000185	CcSEcCtD
Bortezomib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	4.19e-05	0.000185	CcSEcCtD
Bortezomib—Nausea—Indinavir—acquired immunodeficiency syndrome	4.19e-05	0.000184	CcSEcCtD
Bortezomib—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	4.18e-05	0.000184	CcSEcCtD
Bortezomib—Headache—Efavirenz—acquired immunodeficiency syndrome	4.17e-05	0.000184	CcSEcCtD
Bortezomib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	4.17e-05	0.000184	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.14e-05	0.00052	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CD40LG—acquired immunodeficiency syndrome	4.13e-05	0.000519	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.12e-05	0.000518	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CD40LG—acquired immunodeficiency syndrome	4.11e-05	0.000516	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.1e-05	0.000515	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CD40LG—acquired immunodeficiency syndrome	4.09e-05	0.000514	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CSF2—acquired immunodeficiency syndrome	4.08e-05	0.000513	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CD8A—acquired immunodeficiency syndrome	4.08e-05	0.000513	CbGpPWpGaD
Bortezomib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	4.07e-05	0.000179	CcSEcCtD
Bortezomib—PSMD1—Immune System—CSF2—acquired immunodeficiency syndrome	4.06e-05	0.00051	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CD8A—acquired immunodeficiency syndrome	4.06e-05	0.00051	CbGpPWpGaD
Bortezomib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	4.05e-05	0.000178	CcSEcCtD
Bortezomib—PSMD2—Immune System—CD8A—acquired immunodeficiency syndrome	4.04e-05	0.000508	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CSF2—acquired immunodeficiency syndrome	4.04e-05	0.000508	CbGpPWpGaD
Bortezomib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	4.03e-05	0.000178	CcSEcCtD
Bortezomib—Rash—Delavirdine—acquired immunodeficiency syndrome	4.02e-05	0.000177	CcSEcCtD
Bortezomib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	4.01e-05	0.000177	CcSEcCtD
Bortezomib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	4.01e-05	0.000177	CcSEcCtD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	4.01e-05	0.000504	CbGpPWpGaD
Bortezomib—Headache—Delavirdine—acquired immunodeficiency syndrome	3.99e-05	0.000176	CcSEcCtD
Bortezomib—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	3.98e-05	0.000176	CcSEcCtD
Bortezomib—PTGS1—Metabolism—AGPS—acquired immunodeficiency syndrome	3.98e-05	0.000499	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IFNA1—acquired immunodeficiency syndrome	3.95e-05	0.000497	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IFNA1—acquired immunodeficiency syndrome	3.95e-05	0.000497	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IFNA1—acquired immunodeficiency syndrome	3.95e-05	0.000497	CbGpPWpGaD
Bortezomib—Nausea—Efavirenz—acquired immunodeficiency syndrome	3.95e-05	0.000174	CcSEcCtD
Bortezomib—PSMA1—Immune System—HLA-B—acquired immunodeficiency syndrome	3.93e-05	0.000493	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—HLA-B—acquired immunodeficiency syndrome	3.91e-05	0.000491	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IFNA1—acquired immunodeficiency syndrome	3.9e-05	0.00049	CbGpPWpGaD
Bortezomib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	3.9e-05	0.000172	CcSEcCtD
Bortezomib—PSMD2—Immune System—HLA-B—acquired immunodeficiency syndrome	3.89e-05	0.000489	CbGpPWpGaD
Bortezomib—PTGS1—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	3.88e-05	0.000488	CbGpPWpGaD
Bortezomib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	3.88e-05	0.000171	CcSEcCtD
Bortezomib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	3.88e-05	0.000171	CcSEcCtD
Bortezomib—PSMA1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	3.87e-05	0.000486	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	3.85e-05	0.000483	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD79A—acquired immunodeficiency syndrome	3.84e-05	0.000482	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD79A—acquired immunodeficiency syndrome	3.84e-05	0.000482	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD79A—acquired immunodeficiency syndrome	3.84e-05	0.000482	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	3.83e-05	0.000481	CbGpPWpGaD
Bortezomib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	3.83e-05	0.000169	CcSEcCtD
Bortezomib—PSMB1—Disease—CXCR4—acquired immunodeficiency syndrome	3.81e-05	0.000479	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CXCR4—acquired immunodeficiency syndrome	3.81e-05	0.000479	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CXCR4—acquired immunodeficiency syndrome	3.81e-05	0.000479	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD79A—acquired immunodeficiency syndrome	3.79e-05	0.000475	CbGpPWpGaD
Bortezomib—Nausea—Delavirdine—acquired immunodeficiency syndrome	3.78e-05	0.000167	CcSEcCtD
Bortezomib—PSMB8—Disease—CXCR4—acquired immunodeficiency syndrome	3.76e-05	0.000472	CbGpPWpGaD
Bortezomib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	3.75e-05	0.000165	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.75e-05	0.000471	CbGpPWpGaD
Bortezomib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	3.75e-05	0.000165	CcSEcCtD
Bortezomib—PSMD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.73e-05	0.000468	CbGpPWpGaD
Bortezomib—Rash—Ritonavir—acquired immunodeficiency syndrome	3.71e-05	0.000164	CcSEcCtD
Bortezomib—PSMD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.71e-05	0.000466	CbGpPWpGaD
Bortezomib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	3.71e-05	0.000163	CcSEcCtD
Bortezomib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	3.7e-05	0.000163	CcSEcCtD
Bortezomib—Headache—Ritonavir—acquired immunodeficiency syndrome	3.69e-05	0.000163	CcSEcCtD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	3.63e-05	0.000456	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	3.63e-05	0.000456	CbGpPWpGaD
Bortezomib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	3.6e-05	0.000159	CcSEcCtD
Bortezomib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	3.58e-05	0.000158	CcSEcCtD
Bortezomib—Rash—Saquinavir—acquired immunodeficiency syndrome	3.57e-05	0.000157	CcSEcCtD
Bortezomib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	3.57e-05	0.000157	CcSEcCtD
Bortezomib—Headache—Saquinavir—acquired immunodeficiency syndrome	3.55e-05	0.000156	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.52e-05	0.000442	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.52e-05	0.000442	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.51e-05	0.00044	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.51e-05	0.00044	CbGpPWpGaD
Bortezomib—Nausea—Ritonavir—acquired immunodeficiency syndrome	3.5e-05	0.000154	CcSEcCtD
Bortezomib—PSMD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.49e-05	0.000438	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.49e-05	0.000438	CbGpPWpGaD
Bortezomib—PSMA1—Disease—CCR5—acquired immunodeficiency syndrome	3.45e-05	0.000433	CbGpPWpGaD
Bortezomib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	3.44e-05	0.000151	CcSEcCtD
Bortezomib—PSMD1—Disease—CCR5—acquired immunodeficiency syndrome	3.43e-05	0.000431	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CCR5—acquired immunodeficiency syndrome	3.42e-05	0.000429	CbGpPWpGaD
Bortezomib—Rash—Lamivudine—acquired immunodeficiency syndrome	3.41e-05	0.00015	CcSEcCtD
Bortezomib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	3.41e-05	0.00015	CcSEcCtD
Bortezomib—Headache—Lamivudine—acquired immunodeficiency syndrome	3.39e-05	0.000149	CcSEcCtD
Bortezomib—Nausea—Saquinavir—acquired immunodeficiency syndrome	3.37e-05	0.000148	CcSEcCtD
Bortezomib—CYP1A1—Metabolism—TAT—acquired immunodeficiency syndrome	3.29e-05	0.000414	CbGpPWpGaD
Bortezomib—Nausea—Lamivudine—acquired immunodeficiency syndrome	3.21e-05	0.000142	CcSEcCtD
Bortezomib—PSMB5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.14e-05	0.000394	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.14e-05	0.000394	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.14e-05	0.000394	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD40LG—acquired immunodeficiency syndrome	3.13e-05	0.000393	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD40LG—acquired immunodeficiency syndrome	3.13e-05	0.000393	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD40LG—acquired immunodeficiency syndrome	3.13e-05	0.000393	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.1e-05	0.000389	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD8A—acquired immunodeficiency syndrome	3.09e-05	0.000389	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD8A—acquired immunodeficiency syndrome	3.09e-05	0.000389	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD8A—acquired immunodeficiency syndrome	3.09e-05	0.000389	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CSF2—acquired immunodeficiency syndrome	3.09e-05	0.000389	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CSF2—acquired immunodeficiency syndrome	3.09e-05	0.000389	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CSF2—acquired immunodeficiency syndrome	3.09e-05	0.000389	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD40LG—acquired immunodeficiency syndrome	3.09e-05	0.000387	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD8A—acquired immunodeficiency syndrome	3.05e-05	0.000383	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CSF2—acquired immunodeficiency syndrome	3.05e-05	0.000383	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	3.02e-05	0.000379	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HLA-B—acquired immunodeficiency syndrome	2.98e-05	0.000374	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HLA-B—acquired immunodeficiency syndrome	2.98e-05	0.000374	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HLA-B—acquired immunodeficiency syndrome	2.98e-05	0.000374	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HLA-B—acquired immunodeficiency syndrome	2.93e-05	0.000369	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.93e-05	0.000368	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.93e-05	0.000368	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.93e-05	0.000368	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	2.9e-05	0.000364	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.89e-05	0.000363	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.84e-05	0.000357	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.84e-05	0.000357	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.84e-05	0.000357	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.8e-05	0.000352	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.8e-05	0.000352	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	2.7e-05	0.000338	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.68e-05	0.000337	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.67e-05	0.000335	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.67e-05	0.000335	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.67e-05	0.000335	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.67e-05	0.000335	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.67e-05	0.000335	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.67e-05	0.000335	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.67e-05	0.000335	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.65e-05	0.000333	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.64e-05	0.000332	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.63e-05	0.000331	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.63e-05	0.000331	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.63e-05	0.00033	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.62e-05	0.000328	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CCR5—acquired immunodeficiency syndrome	2.61e-05	0.000328	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CCR5—acquired immunodeficiency syndrome	2.61e-05	0.000328	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CCR5—acquired immunodeficiency syndrome	2.61e-05	0.000328	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CCR5—acquired immunodeficiency syndrome	2.58e-05	0.000324	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	2.57e-05	0.000322	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	2.48e-05	0.000311	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	2.46e-05	0.000309	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IFNG—acquired immunodeficiency syndrome	2.43e-05	0.000305	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IFNG—acquired immunodeficiency syndrome	2.42e-05	0.000303	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.41e-05	0.000303	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IFNG—acquired immunodeficiency syndrome	2.41e-05	0.000302	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.4e-05	0.000302	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.39e-05	0.0003	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CD4—acquired immunodeficiency syndrome	2.35e-05	0.000294	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CD4—acquired immunodeficiency syndrome	2.33e-05	0.000293	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CD4—acquired immunodeficiency syndrome	2.32e-05	0.000292	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	2.29e-05	0.000288	CbGpPWpGaD
Bortezomib—PSMA1—Disease—CD4—acquired immunodeficiency syndrome	2.17e-05	0.000272	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IL2—acquired immunodeficiency syndrome	2.16e-05	0.000271	CbGpPWpGaD
Bortezomib—PSMD1—Disease—CD4—acquired immunodeficiency syndrome	2.16e-05	0.000271	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL2—acquired immunodeficiency syndrome	2.15e-05	0.00027	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CD4—acquired immunodeficiency syndrome	2.14e-05	0.000269	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL2—acquired immunodeficiency syndrome	2.14e-05	0.000268	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	2.11e-05	0.000265	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	2.1e-05	0.000264	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	2.09e-05	0.000262	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—ALB—acquired immunodeficiency syndrome	2.06e-05	0.000258	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—ALB—acquired immunodeficiency syndrome	2.05e-05	0.000257	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—ALB—acquired immunodeficiency syndrome	2.04e-05	0.000256	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.03e-05	0.000255	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.03e-05	0.000255	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.03e-05	0.000255	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2e-05	0.000251	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2e-05	0.000251	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2e-05	0.000251	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2e-05	0.000251	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.97e-05	0.000248	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IFNG—acquired immunodeficiency syndrome	1.84e-05	0.000231	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IFNG—acquired immunodeficiency syndrome	1.84e-05	0.000231	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IFNG—acquired immunodeficiency syndrome	1.84e-05	0.000231	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.83e-05	0.00023	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.83e-05	0.00023	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.83e-05	0.00023	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.83e-05	0.00023	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IFNG—acquired immunodeficiency syndrome	1.81e-05	0.000228	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.8e-05	0.000227	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.79e-05	0.000224	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD4—acquired immunodeficiency syndrome	1.78e-05	0.000223	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD4—acquired immunodeficiency syndrome	1.78e-05	0.000223	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD4—acquired immunodeficiency syndrome	1.78e-05	0.000223	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD4—acquired immunodeficiency syndrome	1.75e-05	0.00022	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CD4—acquired immunodeficiency syndrome	1.64e-05	0.000206	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CD4—acquired immunodeficiency syndrome	1.64e-05	0.000206	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CD4—acquired immunodeficiency syndrome	1.64e-05	0.000206	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL2—acquired immunodeficiency syndrome	1.64e-05	0.000205	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL2—acquired immunodeficiency syndrome	1.64e-05	0.000205	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL2—acquired immunodeficiency syndrome	1.64e-05	0.000205	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.62e-05	0.000204	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CD4—acquired immunodeficiency syndrome	1.62e-05	0.000203	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL2—acquired immunodeficiency syndrome	1.61e-05	0.000202	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—ALB—acquired immunodeficiency syndrome	1.56e-05	0.000196	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—ALB—acquired immunodeficiency syndrome	1.56e-05	0.000196	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—ALB—acquired immunodeficiency syndrome	1.56e-05	0.000196	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—ALB—acquired immunodeficiency syndrome	1.54e-05	0.000193	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.4e-05	0.000175	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.39e-05	0.000174	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.38e-05	0.000174	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.38e-05	0.000173	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.29e-05	0.000162	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IL6—acquired immunodeficiency syndrome	1.27e-05	0.000159	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL6—acquired immunodeficiency syndrome	1.26e-05	0.000159	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL6—acquired immunodeficiency syndrome	1.26e-05	0.000158	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.18e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMA1—Disease—IL6—acquired immunodeficiency syndrome	1.17e-05	0.000147	CbGpPWpGaD
Bortezomib—PSMD1—Disease—IL6—acquired immunodeficiency syndrome	1.17e-05	0.000146	CbGpPWpGaD
Bortezomib—PSMD2—Disease—IL6—acquired immunodeficiency syndrome	1.16e-05	0.000146	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.06e-05	0.000133	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.06e-05	0.000133	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.06e-05	0.000133	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.06e-05	0.000133	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.04e-05	0.000131	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	9.62e-06	0.000121	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—acquired immunodeficiency syndrome	9.61e-06	0.000121	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—acquired immunodeficiency syndrome	9.61e-06	0.000121	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—acquired immunodeficiency syndrome	9.61e-06	0.000121	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—acquired immunodeficiency syndrome	9.48e-06	0.000119	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—acquired immunodeficiency syndrome	8.88e-06	0.000111	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—acquired immunodeficiency syndrome	8.88e-06	0.000111	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—acquired immunodeficiency syndrome	8.88e-06	0.000111	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—acquired immunodeficiency syndrome	8.75e-06	0.00011	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	8.22e-06	0.000103	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.2e-06	0.000103	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.16e-06	0.000102	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—acquired immunodeficiency syndrome	8.15e-06	0.000102	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.12e-06	0.000102	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.21e-06	7.8e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.21e-06	7.8e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.21e-06	7.8e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.13e-06	7.69e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—acquired immunodeficiency syndrome	5.74e-06	7.21e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	5.27e-06	6.61e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	4.7e-06	5.9e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	4.32e-06	5.43e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	4.29e-06	5.38e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	3.66e-06	4.6e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.83e-06	3.55e-05	CbGpPWpGaD
